HUMAN MONOCLONAL ANTIBODIES TO TNF: NEW OPPORTUNITIES IN TREATMENT OF JUVENILE IDIOPATHIC SPONDYLITIS
Abstract
Key words: children, juvenile idiopathic spondylitis, adalimumab, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (3): 150–156)
About the Authors
R.V. DenisovaE.I. Alekseeva
References
1. Cassidy J., Petty R. Texbook of paediatric rheumatology. 5 еd. Philadelphia: Elsevier Saunders. 2005.
2. Алексеева Е.И., Григорьева А.А., Денисова Р.В. Причины развития резистентности к ингибиторам ФНО α и пути ее преодоления. Вопросы современной педиатрии. 2009; 8 (6): 42–47.
3. Алексеева Е.И., Лисицин А.О., Карагулян Н.А. Адалимумаб: новые возможности лечения ювенильных артритов. Вопросы современной педиатрии. 2009; 8 (3): 88–94.
4. Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum. 2006; 54 (7): 2136–2146.
5. Davis J.C., Revicki D., van der Heijde D.M. et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007; 57: 1050–1057.
6. Revicki D.A., Luo M.P. et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J. Rheumatol. 2008; 35 (7): 1346–1353.
7. Van der Heijde D., Schiff M.H., Sieper J. et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis. 2009; 68 (6): 922–929.
8. Lambert R.G., Salonen D. et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007; 56 (12): 4005–4014.
9. Van der Heijde D., Pangan A.L., Schiff M.H. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann. Rheum. Dis. 2008; 67 (9): 1218–1221.
10. Rudwaleit M., Claudepierre P., Kron M. et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res. Ther. 2010; 12 (2): 43.
11. Van der Heijde D., Salonen D., Weissman B.N., Landewé R. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 2009; 11 (4): 127.
12. Van der Heijde D.M., Revicki D.A. et al. Physical function, disease activity, and health-related quality of life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res. Ther. 2009; 11 (4): 124.
13. Rudwaleit M., Claudepierre P.J. et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. Rheumatol. 2009; 36 (4): 801–808.
14. Rudwaleit M., Olivieri I., Boki K.A. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford). 2009; 48 (5): 551–557.
15. Sulpice M., Deslandre C.J., Quartier P. Efficacy and safety of TNF alpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine. 2009; 76 (1): 24–27.
Review
For citations:
Denisova R., Alekseeva E. HUMAN MONOCLONAL ANTIBODIES TO TNF: NEW OPPORTUNITIES IN TREATMENT OF JUVENILE IDIOPATHIC SPONDYLITIS. Current Pediatrics. 2011;10(3):150–156.
Email this article 
